Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisdexamfetamine in Adults With ADHD and SCT
NCT02635035Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- Nov 2015
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD), Cognitive Disengagement Syndrome (CDS), sponsored by NYU Langone Health. Started Nov 2015; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)Cognitive Disengagement Syndrome (CDS)
Beyond the preview
Go deeper on NCT02635035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02635035.